查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1970845

慢性肾臟病治疗市场－全球产业规模、份额、趋势、机会、预测：按产品类型、最终用户、地区和竞争对手划分，2021-2031年

Chronic Kidney Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球慢性肾臟病治疗市场预计将从 2025 年的 370.7 亿美元成长到 2031 年的 488.6 亿美元，复合年增长率为 4.71%。

该领域涵盖了治疗肾功能衰退的多种方案，从药物治疗和透析到肾臟移植。推动该领域发展的主要因素是人口老化，这使得人们更容易患上肾衰竭，以及高血压和糖尿病等文明病在全球范围内的日益流行。国际肾臟病学会强调了医疗解决方案的迫切性，并估计到2024年，全球将有超过8.5亿人患有某种形式的肾臟疾病。

市场概览
预测期 2027-2031
市场规模：2025年 370.7亿美元
市场规模：2031年 488.6亿美元
复合年增长率：2026-2031年 4.71%
成长最快的细分市场 诊断段
最大的市场 北美洲

另一方面，由于先进替代疗法和长期肾臟护理费用高昂，市场面临巨大的障碍。在许多发展中地区，由于缺乏完善的医疗基础设施和全面的报销机制，很大一部分人口无法获得必要的治疗。这些经济差距和财务障碍是重大挑战，有可能严重限制全球治疗产业的成长和扩张。

市场驱动因素

糖尿病肾臟病患疾病率的不断上升是全球慢性肾臟病治疗市场的主要驱动力。糖尿病患者的高血糖值会逐渐损害肾臟的过滤功能，最终导致糖尿病肾臟病。这占全球终末期肾病病例的很大一部分。这种关联导致需要治疗性介入和长期管理的患者数量持续增长。根据国际糖尿病联盟（IDF）于2025年4月发布的第11版《糖尿病地图集》，全球11.1%的成年人患有糖尿病，构成了一个庞大的高危险群，极易发生肾臟併发症。

同时，由于新型药物疗法和生物製药的突破性进展，市场正在经历一场变革。这些治疗方法和生物製剂不仅旨在控制症状，而且旨在延缓疾病进展。钠-葡萄糖共同输送体2 (SGLT2) 抑制剂的广泛应用正在创造可观的收入，并有助于改善患者照护。例如，勃林格殷格翰在2025年4月的研发投资报告中宣布，其慢性肾臟病治疗药物恩格列净 (Jardiance) 的销售额成长了14.6%，达到84亿欧元。鑑于目前可用的治疗方法选择有限，此类药物的供应至关重要。根据美国肾臟基金会统计，2024年美国仅有28,492名患者接受了肾臟移植手术，凸显了透析和药物治疗的高度依赖性。

市场挑战

先进替代疗法和长期肾臟护理的高昂费用是全球慢性肾臟病治疗市场扩张的主要障碍。儘管肾衰竭的发生率不断上升，但移植和透析等手术的高成本使许多患者无法获得必要的治疗。在医疗基础设施和报销体係不完善的发展中地区，这个问题尤其严重。因此，经济限制阻碍了治疗方案的推广，使市场无法充分发挥不断成长的患者群体的经济潜力。

根据国际肾臟病学会2024年的数据，仅有28%的参与调查的低收入和中低收入国家能够获得完全由公共资金支持的血液透析服务。这一数字凸显了阻碍这些地区市场扩张的严重经济差距。由于缺乏充足的资金支持，肾臟疾病管理中的关键临床需求无法转化为永续的商业性需求，从而阻碍了整个行业的成长，并将产生收入几乎完全限制在拥有完善医疗保健体系的发达国家。

市场趋势

利用穿戴式和携带式技术进行居家透析的转变正在改变市场格局，缓解了传统医疗机构治疗带来的经济和后勤挑战。这一趋势正在催生高度互联且用户友好的透析系统，使患者能够在家庭中管理末期肾功能衰竭，从而提高生活品质并最大限度地降低医院感染的风险。在远端医疗的临床倡议和有利的报销政策的支持下，这项转变将减轻医疗机构的负担。 DaVita 于 2025 年 5 月发布的《2024 年社区护理报告》显示，超过 15% 的患者正在接受居家透析治疗，这表明医疗服务结构正在向分散式模式转变，这印证了居家透析的广泛应用。

同时，人工智慧（AI）在风险分层和疾病早期检测方面的应用，正在为精准肾臟医学树立新的标准。这使得治疗的重点从被动应对转向主动预测。透过利用新型生物标记和先进的机器学习演算法，医疗专业人员能够比以往更早地识别出肾功能快速下降风险较高的患者，从而及时进行适当的治疗，延缓透析的需求。这项技术进步得益于商业性应用和保险覆盖范围的扩大。例如，Renalistics在2025年3月的半年报告中指出，私人保险对诊断测试的报销比例增加了28%，凸显了人工智慧驱动的诊断技术日益增长的临床和市场价值。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：慢性肾臟病治疗的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 产品类型（诊断、治疗、透析、其他）
    • 按最终用户（医院、诊断检查室、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美慢性肾臟病治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲慢性肾臟病治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区慢性肾臟病治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲慢性肾臟病治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲慢性肾臟病治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球慢性肾臟病治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17682

The Global Chronic Kidney Disease Treatment Market is projected to expand from USD 37.07 Billion in 2025 to USD 48.86 Billion by 2031, registering a CAGR of 4.71%. This sector covers various therapeutic measures designed to handle declining renal function, ranging from pharmacological treatments and dialysis to kidney transplantation. Growth is largely fueled by the rising global prevalence of lifestyle-related conditions such as hypertension and diabetes, in addition to an aging population more prone to renal failure. Highlighting the urgent need for medical solutions, the International Society of Nephrology estimated in 2024 that over 850 million people worldwide were suffering from some form of kidney disease.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 37.07 Billion
Market Size 2031USD 48.86 Billion
CAGR 2026-20314.71%
Fastest Growing SegmentDiagnosis Segment
Largest MarketNorth America

Conversely, the market encounters significant hurdles due to the exorbitant costs linked to advanced replacement therapies and long-term renal care. In numerous developing areas, the absence of adequate healthcare infrastructure and comprehensive reimbursement systems denies a substantial portion of the populace access to essential treatments. These economic disparities and financial obstacles represent a major challenge that threatens to severely limit the wider growth and reach of the global treatment industry.

Market Driver

The rising prevalence of diabetes-related nephropathy acts as a major catalyst for the Global Chronic Kidney Disease Treatment Market. Elevated blood sugar levels in diabetics gradually impair the renal filtration mechanism, resulting in diabetic kidney disease, which constitutes a significant share of end-stage renal disease cases worldwide. This connection guarantees a steady and increasing stream of patients needing therapeutic intervention and chronic management. As noted in the 'IDF Diabetes Atlas 11th Edition' released by the International Diabetes Federation in April 2025, 11.1% of the global adult population is living with diabetes, forming a vast pool of individuals at high risk for renal complications.

Simultaneously, the market is being transformed by breakthroughs in novel pharmacological therapies and biologics that aim to slow disease progression rather than simply address symptoms. The widespread adoption of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors has generated significant revenue and enhanced patient care. For example, Boehringer Ingelheim reported in their April 2025 R&D investment update that sales of Jardiance, a drug for chronic kidney disease, increased by 14.6% to EUR 8.4 billion. This uptake in pharmaceuticals is crucial given the limited availability of cures; the American Kidney Fund noted that only 28,492 patients in the United States received a transplant in 2024, highlighting the heavy dependence on dialysis and medication.

Market Challenge

The exorbitant expenses tied to advanced replacement therapies and long-term renal care create a significant obstacle to the expansion of the Global Chronic Kidney Disease Treatment Market. Despite the increasing incidence of renal insufficiency, the high cost of procedures such as transplantation and dialysis precludes a large segment of patients from receiving essential care. This problem is especially severe in developing regions lacking sufficient healthcare infrastructure and robust reimbursement frameworks. Consequently, the market fails to realize the full economic potential of the expanding patient base, as financial limitations restrict the uptake of therapeutic solutions.

Data from the International Society of Nephrology in 2024 indicates that full public funding for hemodialysis was accessible in merely 28% of participating low and lower-middle-income nations. This figure underscores the profound economic inequality that limits market reach in these areas. In the absence of sufficient funding structures, the critical clinical requirement for kidney disease management cannot evolve into viable commercial demand, thereby hindering broader industry growth and restricting revenue generation largely to developed countries with established healthcare support.

Market Trends

The movement toward home-based dialysis using wearable and portable technologies is transforming the market by mitigating the financial and logistical challenges of conventional in-center care. This trend involves the creation of connected, easy-to-use dialysis systems that enable patients to handle end-stage renal disease from home, enhancing their quality of life while minimizing the risk of hospital-acquired infections. Supported by clinical advocacy for remote care and favorable reimbursement rules, this shift relieves pressure on strained healthcare facilities. As evidence of this growing adoption, DaVita's '2024 Community Care' report from May 2025 noted that over 15% of their patients performed dialysis at home, indicating a structural shift toward decentralized treatment.

Concurrently, the incorporation of artificial intelligence for risk stratification and early disease detection is setting a new standard in precision renal care, shifting the focus from reactive treatment to predictive intervention. By utilizing novel biomarkers and sophisticated machine learning algorithms, medical professionals can detect patients prone to rapid kidney function decline much earlier than before, allowing for timely treatments that delay the need for dialysis. This technological progress is validated by rising commercial adoption and payer coverage; for instance, Renalytix reported in their March 2025 'Half-year Report' that revenue from commercial insurance reimbursed testing rose by 28%, highlighting the growing clinical and market value of AI-powered diagnostics.

Key Market Players

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Chronic Kidney Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Kidney Disease Treatment Market, By Product Type

  • Diagnosis
  • Treatment
  • Dialysis
  • Others

Chronic Kidney Disease Treatment Market, By End User

  • Hospital
  • Diagnostic Laboratories
  • Other

Chronic Kidney Disease Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Kidney Disease Treatment Market.

Available Customizations:

Global Chronic Kidney Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Kidney Disease Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Diagnosis, Treatment, Dialysis, Others)
    • 5.2.2. By End User (Hospital, Diagnostic Laboratories, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Chronic Kidney Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chronic Kidney Disease Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Chronic Kidney Disease Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Chronic Kidney Disease Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By End User

7. Europe Chronic Kidney Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chronic Kidney Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Chronic Kidney Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Chronic Kidney Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Chronic Kidney Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Chronic Kidney Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Chronic Kidney Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Chronic Kidney Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Chronic Kidney Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Chronic Kidney Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Chronic Kidney Disease Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Chronic Kidney Disease Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Chronic Kidney Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Chronic Kidney Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Chronic Kidney Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Chronic Kidney Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By End User

10. South America Chronic Kidney Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Chronic Kidney Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Chronic Kidney Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Chronic Kidney Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Chronic Kidney Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. Bayer AG
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. F. Hoffmann-La Roche Ltd
  • 15.6. GlaxoSmithKline PLC
  • 15.7. Merck & Co. Inc.
  • 15.8. Pfizer Inc.
  • 15.9. Sysmex Corporation
  • 15.10. Teva Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer